MA-BATTERY-VENTURES
15.9.2021 13:02:10 CEST | Business Wire | Press release
Battery Ventures, a global, technology-focused investment firm, promoted software investor Jordan Welu to the role of partner and announced a dozen other internal promotions as it expands the global reach of its venture-capital and private-equity businesses worldwide. Battery is currently investing its 13th family of funds, raised in early 2020 and capitalized at a combined $2 billion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210915005299/en/
Welu, who joined Battery in 2014, is a B2B-tech investor who focuses on growth-stage and buyout investments in areas such as infrastructure software, cybersecurity and financial technology. He is currently involved with Battery portfolio companies Alogent, DomainTools, Forest2Market, Learnosity and Plixer. Previously, he backed Concurrent Real-Time (acquired by Spectris) and Enviance (acquired by Cority).
Prior to Battery, Welu, who is based in Boston, worked in software corporate development and finance at companies including Rogue Wave Software, a former Battery portfolio company, and Webroot. Earlier in his career, he worked in investment banking and equity research. Jordan is a graduate of Georgetown University.
Battery also named two existing team members to the role of principal: Roland Anderson, based in Boston, and Satoshi Harris-Koizumi, based in New York. Both specialize in software investments. Anderson joined Battery in 2014 and Harris-Koizumi in 2012.
There were also six promotions to vice president. These include Danel Dayan and Courtney Chow in Menlo Park; Mike Hoeksema and Viraj Parmar in New York; Lauren Wedell in Boston; and Lior Mallul in Herzliya, Israel. In addition, Battery promoted three team members to associate. These include Maximilian Jessen and Matt Klineman, based in Boston, and Diego Liranzo in New York. Earlier this year, Battery promoted Antonia Heiss, based in London, to associate. Finally, the firm announced it has hired Jenny Kang as the firm’s vice president of talent for venture- and growth-stage companies. Previously, Kang was the head of go-to-market executive recruiting at Sequoia Capital.
“Jordan’s promotion to partner, following his work with Concurrent Real-Time and Enviance, is richly deserved, as are the promotions of all the new principals, vice presidents and associates,” said Jesse Feldman, a Battery general partner who helped make the original investment in Welu’s previous employer Rogue Wave Software. “More broadly, the moves highlight Battery’s longtime preference for promoting talent from within the firm as we seek out the most promising technology investments regardless of stage, sector or geography. We’re also very excited to add Jenny Kang to our team as we continue to offer more value-added services, including recruiting and talent assistance, to our portfolio companies.”
In the last 12 months, Battery has seen seven of its portfolio companies—Affirm, Coinbase, Confluent, JFrog, Olo, Sprinklr and Sumo Logic—stage initial public offerings. Since its founding in 1983 through June 30 of this year, Battery has funded 468 companies, not including seed investments, and realized 185 M&A events and 69 IPOs in total.
About Battery Ventures
Battery partners with exceptional founders and management teams developing category-defining businesses in markets including software and services, enterprise infrastructure, online marketplaces, healthcare IT and industrial technology. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from six strategic locations: Boston; San Francisco and Menlo Park, Calif.; Herzliya, Israel; London; and New York. Follow the firm on Twitter @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005299/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom